Financial Highlights
Consolidated Performance (Includes Noumed from acquisition date)
- Q4FY26 Revenue: ₹198 crore
- Q4FY26 EBITDA: ₹29 crore
- FY26 Consolidated Revenue: ₹381 crore
Standalone Performance (YoY Growth)
- FY26 Revenue: +31%
- FY26 EBITDA: +23%
- FY26 PAT: +64%
- CDMO Revenue: Surged over 250% YoY
Operational Highlights
Portfolio Expansion & Pipeline
- Expanded portfolio by 93 dossiers in FY26:
- 88 regulated/emerging market filings
- 5 TGA Australia dossiers through Noumed
- 67 dossiers currently under development
- Strong visibility for export-led growth in FY27 and beyond
Business Development
- Secured long-term CDMO contracts strengthening revenue visibility
- Enhanced global market access through expansion in Australia and New Zealand
- Deeper engagement with existing customers driving CDMO growth
Acquisition & Corporate Structure
Noumed Pharmaceuticals Acquisition
- Completed acquisition of 74.6% stake in Australia-based Noumed Pharmaceuticals Pty Limited on November 12, 2025
- Includes its wholly owned subsidiary, Noumed Pharmaceuticals Limited (New Zealand)
- Acquisition consideration: ₹129 crore
- Financials consolidated from acquisition date
Group Structure
Consolidated entity includes:
- Sai Parenterals Limited (Parent)
- Revat Laboratories Private Limited (100% subsidiary)
- Sai Parenterals Pte. Ltd., Singapore (100% subsidiary)
- Noumed Pharmaceuticals Pty Limited, Australia (74.6% stake)
- Noumed Pharmaceuticals Limited, New Zealand (wholly owned subsidiary of Noumed Australia)
Manufacturing Facilities & Capacity Expansion
The Company is actively expanding and upgrading facilities to meet growing demand:
Unit I (Injectables - Jeedimetla, Telangana)
- Pre-expansion capacity: 42 million units
- Post-expansion capacity: 78 million units
- Current accreditation: GMP
- Target accreditation: EU-GMP, WHO-GMP, PIC/S
- Expected completion: January 2027
Unit II (Injectables - Jeedimetla, Telangana)
- Pre-expansion capacity: 15 million units
- Post-expansion capacity: 21 million units
- Current accreditation: WHO-GMP
- Target accreditation: EU-GMP, WHO-GMP, PIC/S
- Expected completion: January 2027
Unit III (General Oral Dosage Forms - Bhongir, Telangana)
- Pre-expansion capacity: 240 million units
- Post-expansion capacity: 451 million units
- Current accreditation: TGA-Australia, WHO-GMP, PIC/S
- Target accreditation: TGA-Australia, WHO-GMP, PIC/S
- Capex infusion: ₹311 crore
- Expected completion: October 2026
Unit IV (Cephalosporin Oral & Injectables - Bollaram, Telangana)
- Capacity: 293 million units (no expansion)
- Current accreditation: WHO-GMP, PIC/S
- Target accreditation: EU-GMP, WHO-GMP, PIC/S
- Expected completion: January 2027
Dedicated R&D Facility
- Capex: ₹18 crore
- Purpose: Enhance formulation development capabilities, support new product introduction, accelerate regulatory dossier filing
- Expected completion: July 2027
- Plan to expand R&D headcount by 20 personnel
Noumed Australia Facility (Adelaide)
- Facility under development
- Total project cost: AUD 53 million
- Australian Government grant: AUD 20 million
- Expected completion: Q4FY27
- Will manufacture tablets, liquid orals and nasal sprays
Regulatory Approvals & Certifications
Current Accreditations
- TGA Australia approved manufacturing facility in Hyderabad (Unit III)
- PIC/S approved Cephalosporin manufacturing facility (Unit IV)
- 599 approved product registrations across regulated markets
- 506 product registrations in regulatory markets supporting CDMO operations
Upgradation Plans
- Units I and II undergoing upgradation for EU-GMP approval
- Unit IV in process of upgrading to EU-GMP approval
Market Opportunity
Australia CDMO Market
- Valued at ~$2 billion in 2024
- Expected CAGR: ~11.2%
New Zealand CDMO Market
- Valued at $0.56 billion in 2025
- Expected CAGR: ~17.3%
Intellectual Property & Product Pipeline
- Comprehensive portfolio of 302 complex products covering all critical therapeutic areas
- 456 products approved in TGA-Australia
- 143 approvals in other regulated markets
- Manufacturing capabilities across all dosage forms: liquid and dry powder injectables, tablets, capsules, liquid orals, sprays, ointments and dry syrups
Management Team
Key Personnel
- Mr. Anil Kumar Karusala - Managing Director (DIN: 01866646)
- Vijitha Gorrepati - Whole-time Director
- D B Venkoji Prakash - Chief Executive Officer
- Gurumoorthy Kamma - Head Corporate-Quality Assurance
- Anil Kumar - Chief Financial Officer
- Shivali Aggarwal - Company Secretary and Compliance Officer
Noumed Leadership
- Mark Thulborne - Managing Director, Noumed Pharmaceuticals Pty Limited
- Jo-Maree Delac - Director, Noumed Pharmaceuticals Pty Limited
IPO Proceeds Utilization
Completed IPO in March 2026 with primary fund raise of ₹285 crore. Listed on BSE and NSE on April 02, 2026.
Allocation of Net Proceeds:
- Capacity expansion and upgradation of manufacturing facilities: ₹111 crore
- Establishment of new R&D Centre: ₹18 crore
- Repayment/prepayment of outstanding institutional borrowings: ₹14 crore
- Working capital requirements: ₹33 crore
- Repayment of bridge and term loan for Noumed acquisition: ₹36 crore
- General corporate purposes: ₹8 crore
- Issue expenses: ₹28 crore
Corporate History & Acquisitions
Acquisition Track Record
- 2022: Unit III - TGA Australia approved facility (₹2 crore)
- 2023: Unit IV - PICs approved facility (₹11 crore)
- 2024: Revat Laboratories Private Limited (100%, ₹28 crore)
- 2025: Noumed Pharmaceuticals Pty Ltd including NZ subsidiary (74.6%, ₹129 crore)
Key Strategies
- Expansion into global injectable formulations market
- Capitalize on CDMO opportunity by leveraging commercial manufacturing with enhanced R&D competences
- Strengthening presence in regulated markets through upcoming manufacturing facility at Adelaide, Australia
- Focus on new product development to drive future growth
- Grow Branded Generic Formulations business in international markets